Gary Schaer to Antigens, CD34
This is a "connection" page, showing publications Gary Schaer has written about Antigens, CD34.
Connection Strength
0.994
-
Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model. Catheter Cardiovasc Interv. 2013 May; 81(6):970-7.
Score: 0.428
-
PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. Circ Res. 2017 Jan 20; 120(2):324-331.
Score: 0.141
-
The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. JACC Cardiovasc Interv. 2016 08 08; 9(15):1576-85.
Score: 0.139
-
Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. Cell Transplant. 2016; 25(9):1701-1711.
Score: 0.136
-
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013 Jun; 165(6):854-861.e2.
Score: 0.110
-
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J. 2018 06 14; 39(23):2208-2216.
Score: 0.039